Literature DB >> 1550770

Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection.

J Pont1, E Puchhammer-Stöckl, A Chott, T Popow-Kraupp, H Kienzer, G Postner, N Honetz.   

Abstract

We report a case of persistent infection with human parvovirus B19 (PVB19), manifesting clinically as recurrent agranulocytosis and in bone marrow biopsy as recurrent pure granulocytic aplasia. Persistence of parvovirus infection was documented by the presence of PVB19 DNA and anti-PVB19-IgM antibodies in the serum for a period of 19 months. Granulocytic aplasia occurred only when anti-PVB19-IgG antibodies were not detectable in the serum and granulopoiesis showed immediate recovery with high dose intravenous immunoglobulin treatment. This case report suggests that the erythroid precursor cell may not be the only target cell of PVB19 infection. We suggest testing for active parvovirus infection in cases of aplasia of any lineage of the haematopoietic system.

Entities:  

Mesh:

Year:  1992        PMID: 1550770     DOI: 10.1111/j.1365-2141.1992.tb08894.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.

Authors:  T Saikawa; S Anderson; M Momoeda; S Kajigaya; N S Young
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Modest truncation of the major capsid protein abrogates B19 parvovirus capsid formation.

Authors:  M Kawase; M Momoeda; N S Young; S Kajigaya
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

Review 4.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  A regional experience of red cell aplasia.

Authors:  J A Kynaston; N C West; M M Reid
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

Review 6.  Parvovirus B19 infection.

Authors:  J R Kerr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

7.  Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins.

Authors:  A Gigler; S Dorsch; A Hemauer; C Williams; S Kim; N S Young; S Zolla-Pazner; H Wolf; M K Gorny; S Modrow
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  A case of pure red cell aplasia: follow-up on different immunosuppressive regimens.

Authors:  M Baldus; M Möller; H Walter; H Brass; W Queisser
Journal:  Clin Investig       Date:  1994-12

9.  Lymphoproliferative responses after infection with human parvovirus B19.

Authors:  A von Poblotzki; C Gerdes; U Reischl; H Wolf; S Modrow
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Three Adult Cases of HPV-B19 Infection with Concomitant Leukopenia and Low Platelet Counts.

Authors:  Daizo Yaguchi; Nobuyuki Marui; Masaki Matsuo
Journal:  Clin Med Insights Case Rep       Date:  2015-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.